Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate

Authors

  • Dr. Giancarlo Castaman,

    Corresponding author
    1. Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    • Department of Hematology, San Bortolo Hospital, 1-36100 Vicenza, Italy
    Search for more papers by this author
  • Alberto Tosetto,

    1. Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Search for more papers by this author
  • Francesco Rodeghiero

    1. Department of Hematology and Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy
    Search for more papers by this author

Abstract

A patient with benign monoclonal lgG lambda paraproteinemia, acquired von Willebrand syndrome (AVWS), and chronic melena successfully responding to high-dose intravenous immunoglobulin (lvlg) is reported. Coagulation parameters at admission were APTT (ratio) 1.68; VIII:C 11 IU/dL; vWF:Ag 7 IU/dL: Ricof <3 IU/dl. RIPA was >1.8 mg/ml, and bleeding time (BT) was prolonged (18 min). No evidence for an in vitro inhibitor against the VIII/vWF complex was observed. VIII/vWF measurements showed a short-lived increase after both DDAVP and Hemate P, and BT was transiently normalized. After intravenous lg (1 g/kg for 2 days), VIII/vWF measurements, hemostatic parameters and multimeric pattern were completely corrected (VIII/C 106 IU/dl, vWF:Ag 168 IU/dl, RiC of 147 IU/dl, APTT ratio 0.89, BT 5′), with a return to pre-infusion values after 15 days. Hemoccult test became negative and packed red cell transfusions, of which 130 units were administered during the last year, were no longer required. After 18 months the patient is on maintenance treatment with repeated courses of Ig, at 3 to 4-week intervals based on VIII/vWF and BT monitoring. © 1992 Wiley-Liss, Inc.

Ancillary